FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

23 No-Longer-Marketed ANDAs Withdrawn

Federal Register notice: FDA withdraws approval of 23 ANDAs from multiple applicants after they notified the agency that the products are no longer be...

latest-news-card-1
Human Drugs

AstraZeneca Reports Favorable Calquence Data

AstraZeneca says data from its Phase 3 AMPLIFY trial showed that Calquence (acalabrutinib) in combination with venetoclax showed favorable progression...

latest-news-card-1
Human Drugs

Kaleo Social Media Post Runs Afoul of FDA

FDA cites a Kaleo social media post about Auvi-Q (epinephrine injection) because it presented benefit information but failed to include any risk infor...

latest-news-card-1
Human Drugs

Carie Boyd Pharma Hit with FDA-483

FDA issues Carie Boyd Pharmaceuticals a six-observation Form FDA-483 after inspecting the firms Irving,TX outsourcing facility last month.

latest-news-card-1
Human Drugs

Alpha Cognitions Zunveyl OKd for Alzheimers

FDA approves an Alpha Cognition NDA for ZUNVEYL (benzgalantamine) for treating mild-to-moderate Alzheimers disease.

latest-news-card-1
Medical Devices

Elixir Med. Breakthrough Status for Bioadaptive Implant

FDA grants Elixir Medical a breakthrough device designation for its DynamX Sirolimus-Eluting Coronary Bioadaptor System for use in treating coronary a...

latest-news-card-1
Human Drugs

Syndax Leukemia Review Extended by FDA

FDA extends by three months its review of a Syndax Pharmaceuticals NDA for revumenib and its use in treating adult and pediatric patients with relapse...

latest-news-card-1
Medical Devices

Colon Cancer Blood Test Approved

FDA approves Guardant Healths Shield blood test for colon cancer screening in adults 45 years of age and older who are at average risk for the disease...

latest-news-card-1
Human Drugs

Suns JAK Inhibitor OKd for Alopecia Areata

FDA approves a Sun Pharmaceutical Industries NDA for Leqselvi (deuruxolitinib) 8 mg tablets for treating adults with severe alopecia areata.

latest-news-card-1
Federal Register

Pulmonary-Allergy Drugs Panel Renewal

Federal Register notice: FDA announces the renewal for two years of its Pulmonary-Allergy Drugs Advisory Committee.